Pilot study on a new endoscopic platform for colorectal endoscopic submucosal dissection
- PMID: 37457137
- PMCID: PMC10338719
- DOI: 10.1177/17562848221104953
Pilot study on a new endoscopic platform for colorectal endoscopic submucosal dissection
Abstract
Background: The endoscopic submucosal dissection (ESD) is a technically demanding and time-consuming procedure, with an increased risk of adverse events compared to standard endoscopic resection techniques. The main difficulties are related to the instability of the operating field and to the loss of traction. We aimed to evaluate in a pilot trial a new endoscopic platform [tissue retractor system (TRS); ORISE, Boston scientific Co., Marlborough, MA, USA], designed to stabilize the intraluminal space, and to provide tissue retraction and counter traction.
Method: We prospectively enrolled all consecutive patients who underwent an ESD for sigmoid/rectal lesions. The primary outcome was the rate of technical feasibility. Further technical aspects such as en-bloc and R0 resection rate, number of graspers used, circumferential incision time, TRS assemblage time, submucosal dissection time, and submucosal dissection speed were provided. Clinical outcomes (recurrence rate and adverse events) were recorded as well.
Results: In all, 10 patients (M/F 4/6, age: 70.4 ± 11.0 years old) were enrolled. Eight out of 10 lesions were located in the rectum. Average lesion size was 31.2 ± 2.7 mm, and mean lesion area was 1628.88 ± 205.3 mm2. The two sigmoid lesions were removed through standard ESD, because the platform assemblage failed after several attempts. All rectal lesions were removed in an en-bloc fashion. R0 resection was achieved in 7/8 (87.5%) patients in an average procedure time of 60.5 ± 23.3 min. None of the patients developed neither intraprocedural nor postprocedural adverse events.
Conclusion: TRS-assisted ESD is a feasible option when used in the rectum, with promising result in terms of efficacy and safety outcomes. Nevertheless, our pilot study underlines few technical limitations of the present platform that need to be overcome before the system could be widely and routinely used.
Keywords: ESD; colorectal cancer; endoscopy; hindgut; innovation; mini-invasive.
© The Author(s), 2023.
Conflict of interest statement
Drs Roberta Maselli, Andrea Anderloni, Alessandro Fugazza, and Alessandro Repici received consultancy fees from Boston Scientific. Dr Silvia Carrara received in the last 36 months a research Grant from Boston Scientific on FNB Needles. No further conflict of interest to be disclosed.
Figures



References
-
- Brody H. Colorectal cancer. Nature 2015; 521: S1. - PubMed
-
- Kudo Se, Lambert R, Allen JI, et al.. Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc 2008; 68(4 Suppl): S3–S47. - PubMed
-
- Urban O, Vitek P, Fojtik P, et al.. Laterally spreading tumors-experience based on 138 consecutive cases. Hepatogastroenterology 2008; 55: 351–355. - PubMed
-
- Saito Y, Fukuzawa M, Matsuda T, et al.. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010; 24: 343–352. - PubMed
-
- Terasaki M, Tanaka S, Oka S, et al.. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol 2012; 27: 734–740. - PubMed
LinkOut - more resources
Research Materials
Miscellaneous